AIM: To determine whether adding vitamin D, a potent immunomodulator, improves the hepatitis C virus (HCV) response to antiviral therapy. METHODS: Seventy-two consecutive patients with chronic HCV genotype 1 were rand...AIM: To determine whether adding vitamin D, a potent immunomodulator, improves the hepatitis C virus (HCV) response to antiviral therapy. METHODS: Seventy-two consecutive patients with chronic HCV genotype 1 were randomized into two groups: the treatment group (n = 36, 50% male, mean age 47 ± 11 years) received Peg-α-2b interferon (1.5 μg/kg per week) plus ribavirin (1000-1200 mg/d) together with vitamin D3 (2000 IU/d, target serum level > 32 ng/mL), and the control group (n = 36, 60% male, mean age 49 ± 7 years) received identical therapy without vitamin D. HCV-RNA was assessed by realtime polymerase chain reaction (sensitivity, 10 IU/mL). The sustained virologic response (SVR) was defined as undetectable HCV-RNA at 24 wk post-treatment. RESULTS: Clinical characteristics were similar in both groups. The treatment group had a higher mean bodymass index (27 ± 4 kg/m2 vs 24 ± 3 kg/m2, P < 0.01), viral load (50% vs 42%, P < 0.01), and fibrosis score (> F2: 42% vs 19%, P < 0.001) than the controls. At week 4, 16 (44%) treated patients and 6 (17%) controls were HCV-RNA negative (P < 0.001). At week 12, 34 (94%) treated patients and 17 (48%) controls were HCV-RNA negative (P < 0.001). At 24 wk post-treatment (SVR), 31 (86%) treated patients and 15 (42%) controls were HCV-RNA negative (P < 0.001). Viral load, advanced fibrosis and vitamin D supplementation were strongly and independently associated with SVR (multivariate analysis). Adverse events were mild and typical of Peg-α-2b/ribavirin. CONCLUSION: Adding vitamin D to conventional Peg-α-2b/ribavirin therapy for treatment-na■ve patients with chronic HCV genotype 1 infection significantly improves the viral response.展开更多
In this paper, a surface potential based threshold voltage model of fully-depleted（FD） recessed-source/drain（Re-S/D）silicon-on-insulator（SOI） metal-oxide semiconductor field-effect transistor（MOSFET） is presen...In this paper, a surface potential based threshold voltage model of fully-depleted（FD） recessed-source/drain（Re-S/D）silicon-on-insulator（SOI） metal-oxide semiconductor field-effect transistor（MOSFET） is presented while considering the effects of high-k gate-dielectric material induced fringing-field. The two-dimensional（2D） Poisson＇s equation is solved in a channel region in order to obtain the surface potential under the assumption of the parabolic potential profile in the transverse direction of the channel with appropriate boundary conditions. The accuracy of the model is verified by comparing the model＇s results with the 2D simulation results from ATLAS over a wide range of channel lengths and other parameters,including the dielectric constant of gate-dielectric material.展开更多
目的观察DHS内固定联合药物治疗骨质疏松性股骨粗隆间骨折的临床疗效。方法对46例患者随机采用DHS内固定术手术治疗(对照组)或DHS配合鲑鱼降钙素喷鼻剂加服钙尔奇D片治疗(治疗组),观察比较两组患者在术后4、8、12周末X线表现,6个月后两...目的观察DHS内固定联合药物治疗骨质疏松性股骨粗隆间骨折的临床疗效。方法对46例患者随机采用DHS内固定术手术治疗(对照组)或DHS配合鲑鱼降钙素喷鼻剂加服钙尔奇D片治疗(治疗组),观察比较两组患者在术后4、8、12周末X线表现,6个月后两组患者治疗前后患侧股骨近端(bone mineral density,BMD)值变化和术后疗效。其中治疗组26例,对照组20例,两组在性别、年龄、骨折类型等一般情况方面都具有可比性。结果治疗组患者的骨痂、骨质生成的时间均较对照组明显缩短,生成数量增加,治疗效果明显。治疗6个月后,治疗组治疗后比治疗前患侧股骨近端BMD有所增加(P<0.05),而对照组无明显差异(P>0.05),且治疗组术后疗效的优良率高于对照组(P<0.05),差异有统计学意义。结论DHS内固定联合药物治疗骨质疏松性股骨粗隆间骨折能有效促进骨痂的生长,加速骨折的愈合,减少了患者的卧床时间,促进了早期功能锻炼和患髋的功能恢复。展开更多
文摘AIM: To determine whether adding vitamin D, a potent immunomodulator, improves the hepatitis C virus (HCV) response to antiviral therapy. METHODS: Seventy-two consecutive patients with chronic HCV genotype 1 were randomized into two groups: the treatment group (n = 36, 50% male, mean age 47 ± 11 years) received Peg-α-2b interferon (1.5 μg/kg per week) plus ribavirin (1000-1200 mg/d) together with vitamin D3 (2000 IU/d, target serum level > 32 ng/mL), and the control group (n = 36, 60% male, mean age 49 ± 7 years) received identical therapy without vitamin D. HCV-RNA was assessed by realtime polymerase chain reaction (sensitivity, 10 IU/mL). The sustained virologic response (SVR) was defined as undetectable HCV-RNA at 24 wk post-treatment. RESULTS: Clinical characteristics were similar in both groups. The treatment group had a higher mean bodymass index (27 ± 4 kg/m2 vs 24 ± 3 kg/m2, P < 0.01), viral load (50% vs 42%, P < 0.01), and fibrosis score (> F2: 42% vs 19%, P < 0.001) than the controls. At week 4, 16 (44%) treated patients and 6 (17%) controls were HCV-RNA negative (P < 0.001). At week 12, 34 (94%) treated patients and 17 (48%) controls were HCV-RNA negative (P < 0.001). At 24 wk post-treatment (SVR), 31 (86%) treated patients and 15 (42%) controls were HCV-RNA negative (P < 0.001). Viral load, advanced fibrosis and vitamin D supplementation were strongly and independently associated with SVR (multivariate analysis). Adverse events were mild and typical of Peg-α-2b/ribavirin. CONCLUSION: Adding vitamin D to conventional Peg-α-2b/ribavirin therapy for treatment-na■ve patients with chronic HCV genotype 1 infection significantly improves the viral response.
基金supported by the Science and Engineering Research Board(SERB),Department of Science and Technology,Ministry of Human Resource and Development,Government of India under Young Scientist Research(Grant No.SB/FTP/ETA-415/2012)
文摘In this paper, a surface potential based threshold voltage model of fully-depleted（FD） recessed-source/drain（Re-S/D）silicon-on-insulator（SOI） metal-oxide semiconductor field-effect transistor（MOSFET） is presented while considering the effects of high-k gate-dielectric material induced fringing-field. The two-dimensional（2D） Poisson＇s equation is solved in a channel region in order to obtain the surface potential under the assumption of the parabolic potential profile in the transverse direction of the channel with appropriate boundary conditions. The accuracy of the model is verified by comparing the model＇s results with the 2D simulation results from ATLAS over a wide range of channel lengths and other parameters,including the dielectric constant of gate-dielectric material.
文摘目的观察DHS内固定联合药物治疗骨质疏松性股骨粗隆间骨折的临床疗效。方法对46例患者随机采用DHS内固定术手术治疗(对照组)或DHS配合鲑鱼降钙素喷鼻剂加服钙尔奇D片治疗(治疗组),观察比较两组患者在术后4、8、12周末X线表现,6个月后两组患者治疗前后患侧股骨近端(bone mineral density,BMD)值变化和术后疗效。其中治疗组26例,对照组20例,两组在性别、年龄、骨折类型等一般情况方面都具有可比性。结果治疗组患者的骨痂、骨质生成的时间均较对照组明显缩短,生成数量增加,治疗效果明显。治疗6个月后,治疗组治疗后比治疗前患侧股骨近端BMD有所增加(P<0.05),而对照组无明显差异(P>0.05),且治疗组术后疗效的优良率高于对照组(P<0.05),差异有统计学意义。结论DHS内固定联合药物治疗骨质疏松性股骨粗隆间骨折能有效促进骨痂的生长,加速骨折的愈合,减少了患者的卧床时间,促进了早期功能锻炼和患髋的功能恢复。
